Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

Tumor responses, safety and long-term survivors validate Jennerex

breakthrough product approach

SAN FRANCISCO and YONGIN-SI, South Korea, May 21 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announced today that Phase I clinical trial results from its first-in-class lead product JX-594 were published in the premier journal Lancet Oncology. The majority of these end- stage patients with solid tumors had objective tumor destruction and responses following treatment with the cancer biotherapeutic. Half of the JX-594-treated patients survived for more than eight months, well beyond their life expectancies of three to four months, and four patients with tumor responses survived for 11 to over 18 months. Results were especially promising for liver and lung cancer patients. Importantly, treatment with JX-594 was shown to be well-tolerated. A Phase II clinical trial is now underway for JX-594 in liver cancer. The world-wide liver cancer market is estimated at over one billion dollars per year.

"These clinical results with JX-594 are a major step forward for this novel therapeutic approach that Jennerex is pioneering. We are excited by the potential to help the more than ten thousand patients each year who develop liver cancer in the U.S. alone. These desperate patients represent a huge unmet medical need since few effective therapies are available for them. Our team here at UCSD is extremely excited to be a lead site for the current Phase II trial of JX-594 for liver cancer," said Dr. Tony Reid, M.D., Ph.D., Associate Professor and Director of Clinical Investigation at the University of California, San Diego Moores Cancer Center.

"After years of methodical design and development to optimize our products, these results in end-stage patients powerfully validate our commitment to this breakthrough approach. The clinical results were remarkably similar
'/>"/>

SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/10/2014)... New York (PRWEB) July 10, 2014 ... dedicated to protecting the rights of victims injured ... has brought a lawsuit over allegations that the ... body by a power morcellator used during a ... been filed against Richard Wolf Medical Instruments Corporation ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Most professional football ... return to the game, a new study finds. ... but their rate of return after surgery to fix ... The new study included 60 players who had ... this procedure successfully returned to play, defined as playing ...
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... device developed at the Massachusetts General Hospital (MGH) Center ... can be cultured to establish cell lines for genetic ... issue of Science , an MGH research team ... genetic mutation over time and changing susceptibility to therapeutic ... the blood that represent those present in metastatic deposits, ...
(Date:7/10/2014)... to bump up their grade point averages during college, ... a library or study hall, but in a gym. ... who were members of the recreational sports and fitness ... years had higher GPAs than those who weren,t. ... stayed in school longer. An increase of 3.5 percent ...
Breaking Medicine News(10 mins):Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:Want a higher GPA in college? Join a gym 2
... trial results performed by the Radiation Therapy Oncology ... absence (co-deletion) of chromosomes 1p and 19qhave definitive ... of adult patients with pure and mixed anaplastic ... associated with a substantially better prognosis and near-doubling ...
... 30 per cent of patients hospitalized after a stroke develop ... Researchers found patients who experience delirium after stroke are ... to be discharged to a long-term care facility, nursing home ... recognition and prevention of delirium are important for a quick ...
... HealthDay Reporter , THURSDAY, Jan. 19 (HealthDay News) -- ... child between 2004 and 2008 did not use birth control, and ... a new government study finds. Although the number of teens ... years, the U.S. teen birth rate is still the highest of ...
... now well established, a growing body of research also suggests ... developmental disorder affecting nearly one in 100 children. Using a ... weight is an important environmental factor contributing to the risk ... discordant twins -- twin pairs in which only one twin ...
... THURSDAY, Jan. 19 (HealthDay News) -- Amid hints that statins ... preventing or treating certain types of cancer, new research sheds ... cancer in its tracks among certain women. The ... cells, but some women with breast cancer have mutant forms ...
... gene known as the guardian of the genome is ... aggressive types of cancer, scientists at the European Molecular ... and the University Hospital, all in Heidelberg, Germany, have ... , also presents the first whole genome sequence of ...
Cached Medicine News:Health News:Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor 2Health News:Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor 3Health News:Study finds delirium after stroke linked to poorer outcomes for patients 2Health News:More Than Half of Teens Who Gave Birth Weren't Using Contraception: CDC 2Health News:More Than Half of Teens Who Gave Birth Weren't Using Contraception: CDC 3Health News:Another clue in the mystery of autism 2Health News:Study Hints That Statins Might Fight Breast Cancer 2Health News:Rigged to explode? 2Health News:Rigged to explode? 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: